Trade Alzamend Neuro, Inc. - ALZN CFD

Add to favourite

0.6611

4.06%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0294

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	0.6891
Open*	0.6991
1-Year Change*	25.15%
Day's Range*	0.6611 - 0.7131
52 wk Range	0.84-11.91
Average Volume (10 days)	39.18K
Average Volume (3 months)	2.97M
Market Cap	6.48M
P/E Ratio	-100.00K
Shares Outstanding	7.12M
Revenue	N/A
EPS	-2.32
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	Mar 15, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	0.6891	-0.0120	-1.71%	0.7011	0.7091	0.6657
Apr 17, 2024	0.7191	-0.0210	-2.84%	0.7401	0.7418	0.6916
Apr 16, 2024	0.7492	0.0000	0.00%	0.7492	0.7689	0.7492
Apr 15, 2024	0.7400	-0.1191	-13.86%	0.8591	0.8691	0.7391
Apr 12, 2024	0.8492	-0.0331	-3.75%	0.8823	0.8823	0.8422
Apr 11, 2024	0.8841	-0.0150	-1.67%	0.8991	0.8991	0.8791
Apr 10, 2024	0.8791	0.0100	1.15%	0.8691	0.8991	0.8691
Apr 9, 2024	0.8801	0.0010	0.11%	0.8791	0.8991	0.8761
Apr 8, 2024	0.8791	0.0100	1.15%	0.8691	0.9171	0.8691
Apr 5, 2024	0.8841	-0.0390	-4.22%	0.9231	0.9231	0.8791
Apr 4, 2024	0.8991	0.0150	1.70%	0.8841	0.9261	0.8841
Apr 3, 2024	0.8841	-0.0110	-1.23%	0.8951	0.8951	0.8841
Apr 2, 2024	0.8891	-0.0200	-2.20%	0.9091	0.9091	0.8841
Apr 1, 2024	0.8791	-0.0610	-6.49%	0.9401	0.9490	0.8591
Mar 28, 2024	0.9991	0.0100	1.01%	0.9891	0.9991	0.9791
Mar 27, 2024	1.0191	0.0375	3.82%	0.9816	1.0191	0.9534
Mar 26, 2024	0.9782	-0.0209	-2.09%	0.9991	0.9991	0.9539
Mar 25, 2024	0.9991	-0.0600	-5.67%	1.0591	1.0591	0.9991
Mar 22, 2024	1.0191	-0.0300	-2.86%	1.0491	1.0591	1.0091
Mar 21, 2024	1.0491	0.0200	1.94%	1.0291	1.0791	1.0191

Alzamend Neuro, Inc. Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 16:00	Country US	Event Alzamend Neuro Inc Annual Shareholders Meeting Alzamend Neuro Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, April 30, 2024
Time (UTC) 16:00	Country US	Event Alzamend Neuro Inc Annual Shareholders Meeting Alzamend Neuro Inc Annual Shareholders Meeting Forecast - Previous -
Saturday, July 27, 2024
Time (UTC) 20:00	Country US	Event Q4 2024 Alzamend Neuro Inc Earnings Release Q4 2024 Alzamend Neuro Inc Earnings Release Forecast - Previous -
Wednesday, September 11, 2024
Time (UTC) 20:00	Country US	Event Q1 2025 Alzamend Neuro Inc Earnings Release Q1 2025 Alzamend Neuro Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2023	2022	2021	2020	2019
Total revenue	0	0	0	0	0
Total Operating Expense	14.8705	12.3155	4.88947	4.42416	5.00888
Selling/General/Admin. Expenses, Total	7.42461	7.11822	3.64117	3.35474	1.3088
Research & Development	7.44586	5.20131	1.31072	1.06942	3.70008
Operating Income	-14.8705	-12.3155	-4.88947	-4.42416	-5.00888
Interest Income (Expense), Net Non-Operating	-0.0077	-0.04652	-0.15709	0.01393	0.14639
Net Income Before Taxes	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Net Income After Taxes	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Net Income Before Extra. Items	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Net Income	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Income Available to Common Excl. Extra. Items	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Income Available to Common Incl. Extra. Items	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Diluted Net Income	-14.8782	-12.3621	-5.04657	-4.41024	-4.8625
Diluted Weighted Average Shares	97.519	89.0953	84.9295	84.9295	84.9295
Diluted EPS Excluding Extraordinary Items	-0.15257	-0.13875	-0.05942	-0.05193	-0.05725
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-0.15257	-0.1388	-0.06016	-0.05193	-0.05725
Unusual Expense (Income)	0	-0.004	-0.06242

	Jul 2023	Apr 2023	Jan 2023	Oct 2022	Jul 2022
Total revenue	0	0	0	0	0
Total Operating Expense	3.52593	3.30501	5.42351	3.1064	3.03554
Selling/General/Admin. Expenses, Total	1.15979	1.65694	2.53467	1.57342	1.65959
Research & Development	2.36614	1.64807	2.88885	1.53299	1.37595
Unusual Expense (Income)		0
Operating Income	-3.52593	-3.30501	-5.42351	-3.1064	-3.03554
Interest Income (Expense), Net Non-Operating	-0.00184	-0.00052	-0.00206	-0.00359	-0.00153
Net Income Before Taxes	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Net Income After Taxes	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Net Income Before Extra. Items	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Net Income	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Income Available to Common Excl. Extra. Items	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Income Available to Common Incl. Extra. Items	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Diluted Net Income	-3.52777	-3.30553	-5.42557	-3.10999	-3.03707
Diluted Weighted Average Shares	98.4401	96.7796	98.3262	97.4884	97.4818
Diluted EPS Excluding Extraordinary Items	-0.03584	-0.03416	-0.05518	-0.0319	-0.03116
Dividends per Share - Common Stock Primary Issue	0		0	0	0
Diluted Normalized EPS	-0.03584	-0.03416	-0.05518	-0.0319	-0.03116

Annual
Quarterly

	2023	2022	2021	2020	2019
Total Current Assets	5.83578	14.4135	2.91259	1.81402	1.50092
Cash and Short Term Investments	5.14086	14.0638	1.92927	0.09029	0.04261
Cash	5.14086	14.0638	1.92927	0.09029	0.04261
Total Receivables, Net		0	0.01621	0.19428	0.28535
Accounts Receivable - Trade, Net			0	0.10092	0.20592
Prepaid Expenses	0.69492	0.34972	0.61461	1.52945	1.17296
Total Assets	5.91563	14.5164	2.91259	1.81402	1.50092
Total Current Liabilities	2.87012	1.16493	0.89964	0.99231	1.184
Payable/Accrued	2.87012	1.16285	0.50359	0.92964	1.10467
Notes Payable/Short Term Debt	0	0	0.3353	0	0
Other Current Liabilities, Total	0	0.00208	0.06075	0.06267	0.07933
Total Liabilities	2.87012	1.16493	0.89964	0.99231	1.184
Total Long Term Debt	0	0	0	0	0
Total Equity	3.0455	13.3515	2.01295	0.82171	0.31692
Redeemable Preferred Stock	0	0	0.00008	0.00008	0.00008
Common Stock	0.00969	0.00955	0.00674	0.00648	0.00619
Additional Paid-In Capital	61.9918	57.4198	33.7219	27.5842	22.6863
Retained Earnings (Accumulated Deficit)	-44.0727	-29.1945	-16.8324	-11.7859	-7.37563
Other Equity, Total	-14.8833	-14.8833	-14.8833	-14.9832	-15
Total Liabilities & Shareholders’ Equity	5.91563	14.5164	2.91259	1.81402	1.50092
Total Common Shares Outstanding	6.463	6.36577	5.66225	5.66225	5.66225
Other Current Assets, Total			0.3525
Property/Plant/Equipment, Total - Net	0.07984	0.10291

	Jul 2023	Apr 2023	Jan 2023	Oct 2022	Jul 2022
Total Current Assets	2.4136	5.83578	8.41681	10.3344	12.1147
Cash and Short Term Investments	1.69542	5.14086	7.37584	9.18281	11.5271
Cash	1.69542	5.14086	7.37584	9.18281	11.5271
Total Receivables, Net					0.00941
Accounts Receivable - Trade, Net
Prepaid Expenses	0.71819	0.69492	1.04097	1.15158	0.57813
Total Assets	2.62801	5.91563	8.50198	10.4249	12.2105
Total Current Liabilities	2.74089	2.87012	2.64247	1.63745	1.0287
Payable/Accrued	2.74089	2.87012	2.64247	0.64812	1.0287
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total		0	0	0.98933	0
Total Liabilities	2.74089	2.87012	2.64247	1.63745	1.0287
Total Long Term Debt	0	0	0	0	0
Total Equity	-0.11288	3.0455	5.85951	8.78742	11.1818
Redeemable Preferred Stock	0	0	0	0	0
Common Stock	0.00969	0.00969	0.00964	0.00955	0.00955
Additional Paid-In Capital	62.3611	61.9918	61.5003	59.0027	58.2871
Retained Earnings (Accumulated Deficit)	-47.6004	-44.0727	-40.7671	-35.3416	-32.2316
Other Equity, Total	-14.8833	-14.8833	-14.8833	-14.8833	-14.8833
Total Liabilities & Shareholders’ Equity	2.62801	5.91563	8.50198	10.4249	12.2105
Total Common Shares Outstanding	6.463	6.463	6.42883	6.3666	6.36577
Other Current Assets, Total
Property/Plant/Equipment, Total - Net	0.2144	0.07984	0.08517	0.09049	0.09581

Annual
Quarterly

	2022	2021	2020	2019
Net income/Starting Line	-12.3621	-5.04657	-4.41024	-4.8625
Cash From Operating Activities	-6.61399	-2.71203	-2.34579	-1.0452
Non-Cash Items	4.41734	2.48699	2.36379	2.58743
Changes in Working Capital	1.32718	-0.15245	-0.29935	1.22987
Cash From Investing Activities	-0.10646	0.10092	0.105	0.23409
Other Investing Cash Flow Items, Total	0	0.10092	0.105	0.23409
Cash From Financing Activities	18.855	4.4501	2.28847	0.30872
Financing Cash Flow Items	-0.05867	1.94799	0.00013	0.0727
Issuance (Retirement) of Stock, Net	18.9137	2.1	2.28834	0.23602
Net Change in Cash	12.1345	1.83899	0.04768	-0.5024
Issuance (Retirement) of Debt, Net	0	0.40211
Cash From Operating Activities	0.00355
Capital Expenditures	-0.10646

	Jan 2023	Oct 2022	Jul 2022	Apr 2022	Jan 2022
Net income/Starting Line	-11.5726	-6.14707	-3.03707	-12.3621	-8.49266
Cash From Operating Activities	-6.68797	-4.881	-2.53669	-6.61399	-5.05164
Non-Cash Items	3.0913	1.58298	0.86734	4.41734	3.16357
Changes in Working Capital	1.77563	-0.32933	-0.37405	1.32718	0.27745
Cash From Investing Activities				-0.10646	0
Other Investing Cash Flow Items, Total				0	0
Cash From Financing Activities	0	0	0	18.855	14.9127
Financing Cash Flow Items				-0.05867	0
Issuance (Retirement) of Stock, Net	0	0	0	18.9137	14.9127
Issuance (Retirement) of Debt, Net				0	0
Net Change in Cash	-6.68797	-4.881	-2.53669	12.1345	9.86102
Cash From Operating Activities	0.01774	0.01242	0.0071	0.00355
Capital Expenditures				-0.10646

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alzamend Neuro, Inc. Company profile

About Alzamend Neuro Inc

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).

Industry:

Biotechnology & Medical Research (NEC)

3480 Peachtree Road NE,
Second Floor, Suite 103
ATLANTA
GEORGIA 30326
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024